Lv1
30 积分 2024-05-10 加入
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review
1天前
已完结
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
1天前
已完结
Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes
10天前
已完结
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome
11天前
已关闭
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
11天前
已完结
Independent mechanisms of inflammation and myeloid bias in VEXAS syndrome
1个月前
已完结
Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes
1个月前
已完结
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions
1个月前
已完结
Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes
1个月前
已完结
复发性多软骨炎及VEXAS综合征研究进展
1个月前
已完结
皖公网安备34019202002308
